- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01815359
ICARuS postoperativ intraperitoneal kemoterapi (EPIC) og hypertermisk intraperitoneal kemoterapi (HIPEC) efter optimal cytoreduktiv kirurgi (CRS) for neoplasmer i blindtarmen, tyktarmen eller endetarmen med isoleret peritoneal metastase (ICARuS)
ICARuS (intraperitoneal kemoterapi efter cytoreduktiv kirurgi): Et multicenter, randomiseret fase II-forsøg med tidlig postoperativ intraperitoneal kemoterapi (EPIC) og hypertermisk intraperitoneal kemoterapi (HIPEC) efter optimal cytoreduktiv kirurgi (CRS) for neoplasmer i tyktarmen eller blindtarmen Endetarm med isoleret peritoneal metastase
This is the first randomized trial comparing Early post-operative intraperitoneal chemotherapy (EPIC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for appendiceal and colorectal cancer. The purpose of this study is to find out what effects, good and/or bad, EPIC and HIPEC after cytoreductive surgery have on the patient and the appendiceal, rectal or colon cancer.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Florida
-
Miami, Florida, Forenede Stater
- University of Miami
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63110
- Washington University School of Medicine
-
-
New Jersey
-
Basking Ridge, New Jersey, Forenede Stater, 07920
- Memorial Sloan Kettering Basking Ridge (Consent and Follow up)
-
Middletown, New Jersey, Forenede Stater, 07748
- Memorial Sloan Kettering Monmouth (Consent and Follow up)
-
Montvale, New Jersey, Forenede Stater, 07645
- Memorial Sloan Kettering Bergen (Consent and Follow up)
-
-
New York
-
Commack, New York, Forenede Stater, 11725
- Memorial Sloan Kettering Commack (Consent and Follow up)
-
Harrison, New York, Forenede Stater, 10604
- Memorial Sloan Kettering Westchester (Consent and Follow up)
-
New York, New York, Forenede Stater, 10065
- Memorial Sloan Kettering Cancer Center
-
Uniondale, New York, Forenede Stater, 11553
- Memorial Sloan Kettering Nassau (Consent and Follow up)
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Patient's age 18 years or older, both genders.
- Clinical diagnosis of appendiceal or colorectal neoplasm with peritoneal mucinosis or metastasis.
- Patient must be planning to undergo complete cytoreduction of all peritoneal disease.
- ECOG performance status ≤ 1.
- Hematology: ANC ≥ 1,500/ μL; Platelets > 75,000/ μL.
- Adequate Renal function Creatinine <1.5 x the upper limit of normal (ULN) or calculated creatinine clearance of ≥ 50ml/min.
- Adequate Hepatic function: Bilirubin less than 1.5mg/dL; (except in patients with Gilbert's Syndrome, who must have a total bilirubin less than 3.0mg/dL).
- Women with childbearing potential who are negative for pregnancy test (urine or blood) and who agree to use effective contraceptive method. Reliable contraception should be used from trial screening and must be continued throughout the study. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant.
- A man participating in this study must agree to utilize reliable barrier form of contraception for the duration of the study.
- Signed and dated written informed consent to participate in this clinical trial must be obtained prior to any study procedure.
- Subjects with a history of endometrial cancer are eligible only if they presented with a stage lower than 1A and if the histology was a subtype other than poorly differentiated.
Exclusion Criteria:
- Subjects who have previously undergone intraperitoneal chemotherapy.
- Subjects with classical carcinoid
- Tumors of low malignant potential
- Other prior malignancies, except for cured non-melanoma skin cancer, curatively treated in situ carcinoma of the cervix, adequately treated malignancies for which there has been no evidence of activity for more than 3 years or indolent tumors for which observation over three years is a reasonable option.
- Presence of clinically apparent or suspected metastasis to sites other than lymph nodes or peritoneal surfaces.
- Women who are pregnant or lactating.
- Subjects with a condition which may interfere with the subjects' ability to understand the requirements of the study.
- Active coronary artery disease (defined as unstable angina or a positive cardiac stress test).
- Subjects with a history of coronary artery disease may be included if they have had a normal stress test within 60 days of enrollment and/or were cleared by MSK cardiology.
- Uncontrolled hypertension defined as >140/90 and not cleared for surgery at the time of consent.
- New York Heart Association (NYHA) Class II or higher Congestive heart failure.
- Restrictive or obstructive pulmonary disease that would limit study compliance or place the patient at unacceptable risk for participation in the study.
- History of cerebrovascular disease. that would limit study compliance or place the patient at unacceptable risk for participation in the study.
- Subjects with other concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study or places them at an unacceptable risk for participation in the study.
- Patients with known floxuridine, leucovorin ,or mitomycin allergy.
- Evidence of extensive intraperitoneal adhesions at the time of surgery which prohibits intraperitoneal therapy, as determined by the operating surgeon.
- Any condition that would preclude the ability to deliver appropriate IP therapy.
- Use of an oral medication, lacking a suitable non-oral substitute, that if held for up to ten days, would be felt an unacceptable risk by the investigator.
- Life expectancy < 12 weeks.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Appendiceal, no chemotherapy within 6 months prior to surgery
First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.
|
Optimal Surgical Debulking |
|
Eksperimentel: Appendiceal, chemotherapy within 6 months prior to surgery
First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.
|
Optimal Surgical Debulking |
|
Eksperimentel: Colorectal, no chemotherapy within 6 months prior to surgery
First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.
|
Optimal Surgical Debulking |
|
Eksperimentel: Colorectal, chemotherapy within 6 months prior to surgery
First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.
|
Optimal Surgical Debulking |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
disease-free survival
Tidsramme: 3 years
|
Documentation of tumor recurrence will be made based on surveillance CT/PET CT scans at time points as determined by attending radiologist, with clinical correlation from the treating physician. |
3 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
surgical toxicity grade 3 to 5
Tidsramme: up to 60 days
|
We will evaluate toxicity up to 30 days postoperatively for any surgical Grade 3-5 complications/toxicites or chemotherapy related Grade 4 or 5 toxicities. Surgical morbidity will be graded using the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 |
up to 60 days
|
|
chemotherapy toxicity grade 3 to 5
Tidsramme: up to 60 days
|
We will evaluate toxicity up to 30 days postoperatively for any surgical Grade 3-5 complications/toxicities or chemotherapy related Grade 4 or 5 toxicities. |
up to 60 days
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Garrett Nash, MD, MPH, Memorial Sloan Kettering Cancer Center
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Anslået)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Neoplasmer
- Tarmsygdomme
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Gastrointestinale sygdomme
- Intestinale neoplasmer
- Endetarmssygdomme
- Tyktarmssygdomme
- Cecal neoplasmer
- Cecale sygdomme
- Kolorektale neoplasmer
- Appendiceale neoplasmer
- Organiske kemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Terapeutik
- Kirurgiske procedurer, operative
- Lægemiddelterapi
- Nukleinsyrer, nukleotider og nukleosider
- Enzymer og coenzymer
- Indoler
- Pyrimidin -nukleosider
- Pyrimidiner
- Nukleosider
- Formyltetrahydrofolater
- Tetrahydrofolater
- Folinsyre
- Pterins
- Pteridiner
- Hypertermi, induceret
- Coenzymer
- Quinones
- Aziriner
- Deoxyribonucleosider
- Kombineret modalitetsterapi
- Deoxyuridin
- Uridin
- Mitomycins
- Indolequinones
- Kemoterapi, adjuvans
- Leucovorin
- Mitomycin
- Floxuridin
- Cytoreduktion kirurgiske procedurer
- Hypertermisk intraperitoneal kemoterapi
Andre undersøgelses-id-numre
- 12-289
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .